15 results about "Osteocalcin" patented technology

Methods for treating muscle loss and exercise capacity pathologies by controlling osteocalcin release, and compositions therefor, are provided.

The application discloses a functional composition for improving bone and joint health, a conditioner and application. The functional composition comprises a first active component and a second active component; the first active component comprises elastin peptide, haematococcus pluvialis and ergothioneine; and the second active component comprises one or more of houttuynia cordata and non-denatured type II collagen. The application realizes the protection effect on joint, cartilage and bone health by scientific matching of the components and synergistically improving the glycosaminoglycan level in chondrocytes and the osteocalcin level in osteoblasts. Meanwhile, the components in the functional composition for improving bone and joint health are natural and have good biocompatibility, and have no obvious side effects, so that the application provides a kind of drug or a substitute for the treatment and prevention of bone diseases.

The invention discloses a functional composition capable of improving bone and joint health, a conditioner and application. The functional composition comprises a first active component and a second active component, the first active component is prepared from elastin peptide, haematococcus pluvialis and ergothioneine; the second active component is prepared from one or more of herba houttuyniae and non-denatured type II collagen. Through scientific compatibility of all the components, the levels of glycosaminoglycan in chondrocytes and osteocalcin in osteoblasts are synergistically improved, and the protection effect on joint, cartilage and skeleton health is achieved. Meanwhile, a plurality of components in the functional composition capable of improving the health of the bones and the joints are natural in source, good in biocompatibility and free of obvious side effects, and a medicine or an alternative scheme thereof is provided for treatment and prevention of the bone diseases.

This invention discloses a method and application for regulating fatty liver syndrome based on osteocalcin-adiponectin receptor, relating to the field of livestock and poultry metabolic disease prevention and control technology. The method includes the following steps: clarifying the clinical symptoms and pathological changes of fatty liver syndrome in laying hens; constructing a complementary validation system for fatty liver syndrome models, including an in vivo FLS model in laying hens and an in vitro LMH model of chicken liver cancer cells; using osteocalcin OCN and the adiponectin receptor agonist AdipoRon to target and intervene in the in vivo FLS model and the in vitro LMH model of chicken liver cancer cells, and conducting multi-dimensional detection and evaluation of the regulatory effect; by specifically silencing the expression of AdipoR1 or AdipoR2, comparing changes in lipid deposition and signaling pathways in cells treated with osteocalcin, and identifying the functional hierarchy of AdipoR1 and AdipoR2 in the osteocalcin regulatory pathway; this invention achieves precise prevention and treatment of fatty liver syndrome in laying hens through complementary validation models, targeted intervention with osteocalcin and AdipoRon, and identification of adiponectin receptor function.

The invention discloses application of black bean source oligopeptide in preparation of a product for preventing / treating osteoporosis, and belongs to the technical field of bioactive peptides. According to the black bean source oligopeptide helpful for improving osteoporosis, the black bean source oligopeptide comprises oligopeptide KGVG and / or oligopeptide KIGT; wherein the amino acid sequence of the oligopeptide KGVG is Lys-Gly-Val-Gly, and the amino acid sequence of the oligopeptide KIGT is Lys-Ile-Gly-Thr; the black bean source oligopeptide can directly up-regulate osteoblast activity, enhance expression of BMP-2 and Runx2, improve the level of bone formation marker osteocalcin, remarkably improve the bone density and bone microstructure of ovariectomized mice and enhance bone mechanical strength, is non-toxic to other tissues, can be used as an effective nutrition strategy for treating and relieving osteoporosis, and has broad application prospects. A scientific basis is provided for efficient utilization of the black bean source bioactive peptide.

The present invention discloses polypeptides and related substances against hair loss and dermatitis, and the uses thereof. Particularly, disclosed is the use of an osteocalcin-derived peptide, and homologous polypeptides, polypeptide-derived peptides or derivatives of the polypeptides and polypeptide-derived peptides, which use the osteocalcin-derived peptide as a skeleton and which are derived from different species, in preparing drugs for treating hair follicle recession and / or hair loss caused by psychological stress, seborrheic hair follicle recession and / or hair loss, acne and / or dermatitis caused by psychological stress and seborrheic acne and / or dermatitis. Further disclosed are the use, in preparing drugs, medical cosmetology products, cosmetics, health-care products, foods and additives for preventing and / or treating hair follicle recession, hair loss, acne and dermatitis, of substances capable of binding to a GPR158 receptor and modulating its activity.

The application discloses a functional composition, a conditioner and a use for treating or preventing bone and joint diseases. The composition of the functional composition comprises a first active component and a second active component, wherein the first active component comprises elastin peptide 1-500 mu g / mL, haematococcus pluvialis 40-20 mu g / mL, phyllanthus emblica 8-4 mu g / mL and mussel 1-500 mu g / mL in terms of concentration in the functional composition; and the second active component comprises broccoli water extract and / or boric acid substances. The application realizes the synergistic improvement of glycosaminoglycan and osteocalcin levels by scientific compounding, plays a protective role on joint, cartilage and bone health, and has natural, safe, good biocompatibility and no obvious side effects, and provides a kind of drug or a replacement scheme for bone disease treatment and prevention.

The invention provides an application of osteocalcin or an active fragment thereof in preparation of a medicine for improving a heart function. The invention also provides a pharmaceutical composition for improving the heart function. The pharmaceutical composition comprises a therapeutically effective amount of osteocalcin or an active fragment thereof. The invention discloses and applies the initiative normal form transformation from'block 'to'activation' for the first time, abandons the traditional'channel block 'thought, and initiates a brand new pharmacological approach for stabilizing cardiac electrical activity, treating arrhythmia and improving cardiac functions by'specific activation' of cardiac potassium ion channels. The invention provides a theoretical basis and an application basis of medicines for improving cardiac insufficiency in a wider sense, the endogenous bone-derived hormone OCN or an agonist thereof is developed into a medicine, the potential advantages of high biocompatibility, low immunogenicity and good human body tolerance of the medicine are fully utilized, and a novel biological preparation with better safety is developed.

According to the composite probiotic preparation and the application thereof in preparation of products for improving body metabolism, 15 specific probiotic strains are compounded, all the strains cooperate to adjust body nutrition metabolism and bone tissue metabolism at the same time, and the problem that an existing probiotic preparation is single in function is solved. In the aspect of nutrition metabolism regulation, the levels of serum total protein, albumin and globulin can be increased, the content of essential amino acids such as threonine, methionine and tryptophan in serum can be increased, the protein synthesis capability of the body can be enhanced, the liver synthesis function can be improved, and the nutrition metabolism efficiency of the body can be improved; in the aspect of bone tissue metabolism regulation, the composition can improve the levels of osteocalcin and osteoprotegerin, promote osteoblast activity, inhibit bone resorption, improve the expression levels of TRPV6 and NCX1 in intestinal epithelial cells, enhance intestinal calcium absorption and transepithelial transport efficiency, reduce the thickness variance of tibia trabecula, improve the tibia microstructure and maintain the uniformity and steady state of a bone tissue structure.

The invention discloses an application of an expression inhibitor of a muscular blind splicing regulator 1 (MBNL1) in promoting osteogenic differentiation and bone formation of bone marrow mesenchymal stem cells (BMSCs), and particularly discloses an application of the expression inhibitor of the MBNL1 in promoting osteogenic differentiation and bone formation of the BMSCs (bone marrow mesenchymal stem cells). According to the present invention, the in-vitro experiment results prove that the si-MBNL1 transfection on the BMSCs can promote the formation of osteoblast calcium nodules, the activity of the marker enzyme ALP, and the expression of the osteogenic related factor Runt related transcription factor 2 (RUNX2), the ALP, the osteopontin (OPN) and the osteocalcin (OCN), and can improve the osteogenic differentiation ability of the BMSCs, such that the si-MBNL1 transfection on the BMSCs can provide the osteogenic differentiation ability of the BMSCs, and further provide the application of the si-MBNL1 transfection on the BMSCs, and the application of the si-MBNL1 transfection on the BMSCs to the osteogenic differentiation of the BMSCs, according to the invention, an adeno-associated virus 9 (AAV9) carrier is used for constructing an sh-MBNL1 regulation technology as an MBNL1 expression inhibitor, and in-vivo experiments prove that the sh-MBNL1 expression inhibitor can be used for repairing estrogen deficiency type osteoporosis bone loss and promoting fracture healing. According to the invention, a breakthrough direction is provided for clinical early warning of osteoporosis, and a new technical means is provided for clinical osteoporosis or gene therapy for promoting fracture healing.

The invention provides an application of the lactobacillus rhamnosus GOLDGUT-M520 in preparation of products for promoting nutrition digestion and absorption and improving bone health, and the lactobacillus rhamnosus GOLDGUT-M520 has dual functions: on one hand, the lactobacillus rhamnosus GOLDGUT-M520 can promote digestion of starch, protein and fat and absorption of mineral substances such as zinc, iron and calcium; the intestinal form is improved, the body protein and amino acid level is improved, and the intestinal flora balance is regulated; on the other hand, the absorption efficiency of intestinal calcium can be improved, the levels of osteocalcin and osteoprotegerin are improved, and the microstructure and mechanical properties of bone tissues are improved. The strain can be applied to the fields of food, health care products and medicines, products with dual functions are developed, dual guarantee is provided for body nutrition supply and bone homeostasis, health collaborative maintenance is achieved, and the application value is remarkable.

The present application relates to the use of plasma osteocalcin as a biomarker in the preparation of a diagnostic and / or prognostic product for sepsis in children. The prognostic product uses the measurement of osteocalcin levels on the first day of admission of a child with sepsis to assess the degree of organ dysfunction and the need for organ support in patients with sepsis. The present application discloses the potential of osteocalcin as a modulator of the immune inflammatory response in sepsis and that its level changes can be used as a predictive marker of the diagnosis and clinical outcome of sepsis. This finding provides a new biomarker for the early diagnosis, prognosis evaluation and treatment of sepsis and an important basis for clinical management.

The present invention relates to a blood osteocalcin secretion promoter containing fucosylated chondroitin sulfate.

Exemplary methods, compositions and uses thereof can be provided for preventing, reducing and / or treating loss of muscle function. In particular, e.g., it is possible to administer to a subject a pharmaceutical composition comprising a therapeutically effective amount of an agent that enhances Interleukin-6 (IL) release during exercise, and optionally a pharmaceutically acceptable carrier or excipient.

The application discloses a probiotic microecological preparation for promoting height growth of children and application thereof, and is characterized by comprising at least one of a fermented Lactobacillus mui ZGG35 strain with a preservation number of CGMCC No. 37997 and a plant Lactobacillus lactis ZGG180 strain with a preservation number of CGMCC No. 37998. The fermented Lactobacillus mui ZGG35 and the plant Lactobacillus lactis ZGG180 are inoculated into a fermentation culture medium at a proportion of 15% in volume ratio to obtain lactic acid bacteria culture, and the ZGG35 bacterial liquid and / or the ZGG180 bacterial liquid is added into a freeze-drying agent to prepare the probiotic microecological preparation. The probiotic microecological preparation has the advantages that the levels of growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein, alkaline phosphatase, osteocalcin, type I procollagen amino-terminal propeptide, insulin, leptin and vitamin D in serum can be improved, and the levels of IL-6 and CTX-I can be reduced.